论文部分内容阅读
目的:研究阿托伐他汀对颈动脉狭窄并支架置入术后患者临床预后及炎症因子的影响。方法:选取2013年1月到2014年1月我院收治的接受支架置入术的颈动脉狭窄患者90例,按照随机数字表法将患者分为研究组和对照组,每组45例,对照组给予常规治疗,研究组在对照组的基础上给予阿托伐他汀治疗,连续治疗1年,比较两组支架内再狭窄率及不良反应发生率,分析治疗前和治疗后两组超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)水平。结果:研究组1年内支架再狭窄率显著低于对照组,两组比较差异具有统计学意义(P<0.05);治疗后两组hs-CRP和IL-6水平均显著低于治疗前,且研究组显著低于对照组,比较差异具有统计学意义(P<0.05);两组不良反应比较无统计学意义(P>0.05)。结论:阿托伐他汀治疗颈动脉狭窄并支架置入术患者,能显著降低支架内再狭窄率及炎症因子水平。
Objective: To study the effects of atorvastatin on the clinical prognosis and inflammatory factors in patients with carotid artery stenosis after stenting. Methods: From January 2013 to January 2014, 90 patients with carotid artery stenosis admitted to our hospital from January 2013 to January 2014 were divided into study group and control group according to random number table method, with 45 cases in each group. Group were given conventional treatment, the study group was given atorvastatin on the basis of the control group, continuous treatment for 1 year, the stent restenosis rate and incidence of adverse reactions were compared between the two groups before and after treatment to analyze the two groups of hypersensitivity C Reactive protein (hs-CRP), interleukin-6 (IL-6) levels. Results: The restenosis rate of the study group was significantly lower than that of the control group in one year (P <0.05), and the levels of hs-CRP and IL-6 in the two groups were significantly lower than those before treatment The study group was significantly lower than the control group, the difference was statistically significant (P <0.05); two groups of adverse reactions was not statistically significant (P> 0.05). Conclusion: Atorvastatin can reduce the rate of restenosis and the level of inflammatory cytokines in patients with carotid stenosis and stenting.